Drug intelligence / Profile preview

CollaGUARD Ag

Development stage: Preclinical
Lead developer: Innocoll
Modality: Recombinant Proteins and Enzymes
Administration: Topical

Overview

CollaGUARD Ag is a collagen-based bioactive wound dressing impregnated with silver, designed for the management of infected wounds or wounds at risk of infection. Developed by Innocoll using its proprietary CollaRx and LiquiColl collagen technologies, the product combines the structural and healing properties of type I collagen with the antimicrobial activity of silver. It serves as a follow-up to the original CollaGUARD product, functioning as a medical device that provides a scaffold for tissue growth while maintaining a sterile environment to prevent or treat localized infection.

Brand names: CollaGUARD Ag

Targets

COL1 (Collagen type I)

Beyond the preview

Go deeper on CollaGUARD Ag.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CollaGUARD Ag.

Explore the full profile